BioNxt Solutions Prepares for Human Bioequivalence Study For MS
VANCOUVER, BC / ACCESS Newswire / April 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to report advanced preparation for its human bioequivalence study for its lead Multiple Sclerosis (MS) treatment.
BioNxt's lead product, BNT23001, is a proprietary sublingual thin-film formulation of Cladribine for the treatment of MS. Preclinical studies, as reported in internal research data and third-party evaluations, have demonstrated high absorption rates and bioequivalence compared to existing oral tablet therapies. The Company has purchased Cladribine active pharmaceutical ingredient which is necessary to complete the technology transfer process with Gen-Plus, its European Contract Research and Development Organization (CRDO), in Munich, Germany. Once commenced, the bioequivalence study is relatively short, scheduled for less than 30 days from start to finish.
The Company plans to make further updates in the coming weeks regarding its bioequivalent study preparation and scheduling, as well integration of its research and development operations with Gen-Plus.
BNT23001 offers a novel approach to MS management by addressing limitations in traditional oral therapies. Its sublingual thin-film format provides:
Convenience: Easy-to-use and portable, ideal for patients with difficulty swallowing or active lifestyles.
Rapid Absorption: Direct delivery through the sublingual mucosa for faster therapeutic action.
Improved Compliance: A patient-friendly alternative designed to enhance adherence to prescribed regimens.
By delivering these advantages, BNT23001 aligns with BioNxt's mission to improve outcomes for patients living with chronic diseases like MS.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 778.598.2698
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BioNxt's sublingual drug products, as well as projected milestones, anticipated partnerships, and potential market opportunities. Forward-looking statements are inherently subject to significant risks, uncertainties, and assumptions, many of which are beyond BioNxt's control. Factors that could cause actual results to differ materially include, but are not limited to, delays in regulatory approvals, negative outcomes from clinical trials, changes in market demand, fluctuations in funding availability, or disruptions in supply chains. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results may differ materially from those expressed or implied. BioNxt undertakes no obligation to update or revise forward-looking statements, except as required by law. Factors that could cause actual results to differ materially from those projected include changes in market demand, regulatory developments, delays in clinical trials, fluctuations in financing availability, supply chain disruptions, and unforeseen competitive pressures.
SOURCE: BioNxt Solutions Inc.
View the original press release on ACCESS Newswire
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
TruMerit and NAPNAP Team Up to Develop a Global Micro-credential for Pediatric Nursing Care17.12.2025 18:45:00 CET | Press release
PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / December 17, 2025 / TruMerit, a worldwide leader in international credentials evaluation to support health worker careers, and the National Association of Pediatric Nurse Practitioners (NAPNAP), The Leader in Pediatric Education for Nurse Practitioners®, have announced they will jointly develop a global micro-credential to help advance the knowledge and skills of the world's pediatric nursing workforce. The collaboration aims to improve health outcomes for infants, children, adolescents, and young adults worldwide amid a global shortage of pediatric nurses that is limiting access to evidence-based pediatric care in countries of all income levels. The partners envision that their micro-credential program will be the centerpiece of a larger initiative to engage global stakeholders in educating, assessing, and credentialing the nursing workforce in this specialization. A micro-credential is a short, competency-based recognition for specific s
SK tes Achieves NCSC CAS-S Accreditation for Comprehensive Onsite and Offsite Data Destruction and Sanitisation Services Across the UK17.12.2025 15:00:00 CET | Press release
LONDON, UK / ACCESS Newswire / December 17, 2025 / SK tes, a global leader in secure technology lifecycle management, is proud to announce that both its UK sites - Cannock, West Midlands and Irvine, Scotland - have achieved accreditation to the Sanitisation Assurance (CAS-S) Scheme by the UK's National Cyber Security Centre (NCSC) for its secure on-site shredding service. This dual-site accreditation enables SK tes to deliver secure data destruction and sanitisation services nationwide from these two strategic locations, to support clients across the whole of the UK. The CAS-S scheme certifies commercial IT asset sanitisation providers to rigorous government standards, ensuring central government (HMG) customers can easily access services that fully comply with NCSC requirements. With this accreditation, SK tes is authorised to provide: Mobile (offsite) destruction services up to SECRET: Devices are destroyed at the client's premises, ensuring sensitive information never leaves the org
AWM Wraps Up 2025 with Multiple Surf Venue Grand Openings16.12.2025 16:05:00 CET | Press release
Ending the Year on a High Note SOLANA BEACH, CA / ACCESS Newswire / December 16, 2025 / American Wave Machines, the surf technology company behind PerfectSwell® Surf Venues worldwide, concludes banner year with two grand openings and expansion into new markets. São Paulo Surf Club Key Year End Highlights: Riyue Bay: November 11 China Tourism Group celebrated the grand opening of PerfectSwell® Riyue Bay Surf Resort Zion: November 20 The Foundation Ceremony of PerfectSwell® Zion took place in Utah. São Paulo: November 29 JHSF celebrated the grand opening of São Paulo Surf Club "This year's results reflect a herculean effort from the team on improving efficiency, product delivery and commissioning. Finishing with two grand openings in one month is perhaps our most notable achievement. With PerfectSwell® Zion well underway and a third pool starting up in Brazil, 2026 will be just as memorable." - CEO Bruce McFarland "The wave quality achievements made this year have exceeded the expectatio
Eastman, AstraZeneca, Kraft Heinz, and P&G Recognized with OMP Supply Chain Awards16.12.2025 15:00:00 CET | Press release
MIAMI, FLORIDA / ACCESS Newswire / December 16, 2025 / AstraZeneca, Eastman, Kraft Heinz, and P&G have been recognized for their outstanding contribution at the recent OMP Conference. The four industry leaders were honored at the Miami event for their commitment to innovation and excellence, while driving real-world results across their global operations. The OMP Awards program turns the spotlight on organizations within the OMP Community that set new benchmarks in supply chain planning and inspire cross-industry progress and transformation. Eastman: Co-shaping Unison Planning™ in a long-term partnership A strategic OMP customer for nearly two decades, Eastman received the Long‑Term Partnership Award for co‑shaping the chemical industry solution of Unison Planning™. Eastman's vision and intense collaboration have helped redefine best practices in chemical supply chain planning and have been a positive influence on broader industry standards. Accepting the award, Baptiste Lebreton, Digi
The U.S. Polo Assn. Palm Beaches Marathon Celebrates Record-Breaking Weekend in West Palm Beach, Florida16.12.2025 13:00:00 CET | Press release
Thousands of Runners From Around the World Participate in South Florida Race Weekend, With Ivan Gabriel Mafla Bolanos of Ecuador Finishing First Overall WEST PALM BEACH, FLA. / ACCESS Newswire / December 16, 2025 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), proudly celebrated an unforgettable race weekend as first-time Title Sponsor of the 2025 U.S. Polo Assn. Palm Beaches Marathon. The race weekend brought extraordinary energy to Downtown West Palm Beach, powered by more than 6,100 participants, representing 29 countries and 46 states. The race, a Boston Marathon qualifier, was supported by more than 200 dedicated volunteers, including employees from USPA Global, the company that manages the global, multi-billion-dollar U.S. Polo Assn. brand. The U.S. Polo Assn. Palm Beaches Marathon was broadcast live for five hours by the Official Broadcast Station, WPBF 25 (ABC, West Palm Beach). The U.S. Polo Assn. Palm Beaches Marathon was won by Ivan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom